Nandrolone decanoate reduces serum lipoprotein(A) concentrations in hemodialysis patients

American Journal of Kidney Diseases

Volumn 29, Issue 4, 1997, Pages 569-575

  Teruel, José L ^a   Lasuncion, Miguel A ^a   Rivera, Maite ^a   Aguilera, Abelardo ^a   Ortega, Henar ^a   Tato, Ana ^a   Marcen, Roberta ^a   Ortuño, Joaquín ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Androgens; apolipoproteins; hemodialysis; lipoprotein(a); lipoproteins

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; NANDROLONE DECANOATE; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEMODIALYSIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE;

EID: 0031003243     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90340-1     Document Type: Article

References (43)

1. Teruel JL, Marcén R, Navarro-Antolin J, Aguilera A, Fernández-Juarez G, Ortuño J: Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients. A prospective study. J Am Soc Nephrol 7:140-144, 1996
2. Aguilera A, Teruel JL, Navarro Antolin J, Garcia Otero G, Marcen R, Liaño F, Ortuño J: Has androgen a role in the erythropoietin era? J Am Soc Nephrol 5:430, 1994 (abstr)
3. Glazer G: Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 151:1925-1933, 1991
4. Cattran DC, Fenton SSA, Wilson DR, Oreopoulos D, Shimizu A, Richardson RM: A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney Int 12:430-437, 1977
5. Pierides AM, Weightman D, Goldfinch M, Tsoukantas A, Kerr DNS: Serum lipids in uraemic patients on regular haemodialysis. Proc Eur Dial Transplant Assoc 12:397-402, 1975
6. Haupt HA, Rovere GD: Anabolic steroids: A review of the literature. Am J Sports Med 12:469-484, 1984
7. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli FL, Sady MA, Herbert PN: Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261:1165-1168, 1989
8. Friedl KE, Hannan CJ, Jones RE, Plymate SR: High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 39:69-74, 1990
9. Glazer G, Suchman AL: Lack of demonstrated effect of nandrolone on serum lipids. Metabolism 43:204-210, 1994
10. Alvarez JJ, Lasunción MA, Olmos JM, Herrera E: Interindividual variation in the partition of lipoprotein(a) into lipoprotein subfractions. Clin Biochem 96:399-408, 1993
11. Chan MK: Lipid metabolism in renal failure. Clin Biochem 23:61-65, 1990
12. Attamn P-O, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21:573-592, 1993
13. Auguet T, Sentí M, Rubiés-Prat J, Pelegrí A, Pedro-Botet J, Nogués X, Romero R: Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: Influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 8:1099-1103, 1993
14. Prata MM, Sousa FT, Barbas JM, Rodrigues MC: Blood lipids in hemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 5:474, 1990 (letter)
15. Mat O, Stolear JC, Georges B: Blood lipids profile in haemodialysis patients treated with human erythropoietin. Nephron 60:236-237, 1992
16. Pollock CA, Wyndham R, Collett PV, Elder G, Field MJ, Kalowski S, Lawrence JR, Waugh DA, George CRP: Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 45:897-902, 1994
17. Applebaum-Bowden D, Haffner SM, Hazzard WR: The dyslipoproteinemia of anabolic steroid therapy: Increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein cholesterol. Metabolism 36:949-952, 1987
18. Tenover JS: Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75:1092-1098, 1992
19. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM: Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary disease documented by angiography. Circulation 74:758-765, 1986
20. García-Frade FJ, Alvarez JJ, Rayo I, Torrado MC, Lasunción MA, García-Avello A, Marín E: Fibrinolytic parameters and lipoprotein(a) levels in plasma of patients with coronary artery disease. Thrombosis Res 63:407-418, 1991
21. Rader DJ, Hoeg JM, Brewer HB Jr: Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 120:1012-1025, 1994
22. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
23. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: High serum lipoprotein (a) concentrations in uraemic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 38:271-276, 1992
24. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA: Lipids and lipoprotein (a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 10:354-357, 1995
25. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chesnutt CH, Hazzard WR: Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta 795:293-296, 1984
26. Glueck CJ, Freiberg R, Glueck HI, Tracy T, Stroop D, Wang Y: Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with stanozolol. Am J Hematol 48:213-220, 1995
27. Farish E, Rolton HA, Barnes JF, Hart DM: Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. BMJ 303:694, 1991
28. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL: Testosterone decreases lipoprotein(a) in men. Am J Cardiol 77:1244-1247, 1996
29. Scanu AM: Lipoprotein(a): A genetically determined cardiovascular pathogen in search of a function. J Lab Clin Med 116:142-146, 1990
30. Lasunción MA, Alvarez JJ, Herrera E: La lipoproteina(a): De lipoproteina pre-Beta oculta a factor de riesgo cardiovascular. Med Clin (Barc) 101:424-430, 1993
31. Klezovitch O, Scanu AM: Heterogeneity of lipoprotein(a): Growing complexities. Curr Opin Lipidol 6:223-228, 1995
32. Rader DJ, Mann WA, Cain W, Kraft H-G, Usher D, Zecch LA, Hoeg JM, Davignon J, Lupien P, Grossman M, Wilson JM, Brewer HB Jr: The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 95:1403-1408, 1995
33. Lasunción MA, Teruel JL, Alvarez JJ, Carrero P, Ortuño J, Gómez-Coronado D: Changes in lipoprotein(a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolemic patients treated with dextran sulfate LDL-apheresis. Eur J Clin Invest 23:819-826, 1993
34. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 93:2758-2763, 1994
35. Pazos F, Alvarez JJ, Rubiés-Prat J, Varela C, Lasunción MA: Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab 80:562-566, 1995
36. Maher VMG, Brown BG: Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 6:229-235, 1995
37. Waxman DJ, Dannan GA, Guenguerich FP: Regulation of rat hepatic cytochrome P-450: Age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry 24:4409-4417, 1985
38. Chaterjee B, Ozbilen O, Majumdar D, Roy AK: Molecular cloning and characterization of the DNA for androgen repressible rat liver protein SMP-2. J Biol Chem 262:822-825, 1987
39. Neff MS, Eiser AR, Slifkin RF, Baum M, Baez A, Gupta S, Amarga E: Patients surviving 10 years of hemodialysis. Am J Med 74:996-1004, 1983
40. Manske CL: Low HDL cholesterol is not associated with coronary artery disease in azotemic diabetics. Kidney Int 37:280, 1990 (abstr)
41. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N: The uremic dyslipemia: A cross-sectional and longitudinal study. Am J Kidney Dis 20:325-335, 1992
42. Goldwasser P, Michel M-A, Collier J, Mittman N, Fein PA, Gusik S-A, Avram MM: Prealbumin and lipoprotein (a) in hemodialysis: Relationships with patient and vascular access survival. Am J Kidney Dis 22:215-225, 1993
43. Avram MM, Mittman N, Bonomini L, Chattopadhyay J, Fein P: Markers for survival in dialysis: A seven-year prospective study. Am J Kidney Dis 26:209-219, 1995